Literature DB >> 11882758

Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications.

Ramsey M Dallal1, Brian G Harbrecht, Arthur J Boujoukas, Carl A Sirio, Linda M Farkas, Kenneth K Lee, Richard L Simmons.   

Abstract

OBJECTIVE: To review the epidemiology and characteristics of patients who died or underwent colectomy secondary to fulminant Clostridium difficile colitis. SUMMARY BACKGROUND DATA: In patients with C. difficile colitis, a progressive, systemic inflammatory state may develop that is unresponsive to medical therapy; it may progress to colectomy or death.
METHODS: The authors reviewed 2,334 hospitalized patients with C. difficile colitis from January 1989 to December 2000. Sixty-four patients died or underwent colectomy for pathologically proven C. difficile colitis.
RESULTS: In 2000, the incidence of C. difficile colitis in hospitalized patients increased from a baseline of 0.68% to 1.2%, and the incidence of patients with C. difficile colitis in whom life-threatening symptoms developed increased from 1.6% to 3.2%. Forty-four patients required a colectomy and 20 others died directly from C. difficile colitis. Twenty-two percent had a prior history of C. difficile colitis. A recent surgical procedure and immunosuppression were common predisposing conditions. Lung transplant patients were 46 times more likely to have C. difficile colitis and eight times more likely to have severe disease. Abdominal computed tomography scan correctly diagnosed all patients, whereas 12.5% of toxin assays and 10% of endoscopies were falsely negative. Patients undergoing colectomy for C. difficile colitis had an overall death rate of 57%. Significant predictors of death after colectomy were preoperative vasopressor requirements and age.
CONCLUSIONS: C. difficile colitis is a significant and increasing cause of death. Surgical treatment of C. difficile colitis has a high death rate once the fulminant expression of the disease is present.

Entities:  

Mesh:

Year:  2002        PMID: 11882758      PMCID: PMC1422442          DOI: 10.1097/00000658-200203000-00008

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  22 in total

1.  Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.

Authors:  J Salcedo; S Keates; C Pothoulakis; M Warny; I Castagliuolo; J T LaMont; C P Kelly
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

2.  Evaluation of four methods for detection of Clostridium difficile or C. difficile toxin: cytotoxin assay, culture, latex agglutination, and a new rapid immunoassay (C. difficile toxin A test).

Authors:  M Fille; C Larcher; M P Dierich; F Allerberger
Journal:  Z Gastroenterol       Date:  1998-02       Impact factor: 2.000

3.  Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract.

Authors:  C P Kelly; S Chetham; S Keates; E F Bostwick; A M Roush; I Castagliuolo; J T LaMont; C Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

4.  Timing of surgery for fulminating pseudomembranous colitis.

Authors:  K Synnott; K Mealy; C Merry; L Kyne; C Keane; R Quill
Journal:  Br J Surg       Date:  1998-02       Impact factor: 6.939

Review 5.  Immune response to Clostridium difficile infection.

Authors:  C P Kelly
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-11       Impact factor: 2.566

6.  Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats.

Authors:  I Castagliuolo; A C Keates; B Qiu; C P Kelly; S Nikulasson; S E Leeman; C Pothoulakis
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

7.  Clostridium difficile toxin A stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells.

Authors:  I Castagliuolo; A C Keates; C C Wang; A Pasha; L Valenick; C P Kelly; S T Nikulasson; J T LaMont; C Pothoulakis
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

Review 8.  Pathogenesis of Clostridium difficile infection.

Authors:  S P Borriello
Journal:  J Antimicrob Chemother       Date:  1998-05       Impact factor: 5.790

Review 9.  Treatment of Clostridium difficile infection.

Authors:  M H Wilcox
Journal:  J Antimicrob Chemother       Date:  1998-05       Impact factor: 5.790

Review 10.  The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease.

Authors:  R C Spencer
Journal:  J Antimicrob Chemother       Date:  1998-05       Impact factor: 5.790

View more
  157 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

Review 2.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

Review 3.  Clostridium difficile in the ICU: the struggle continues.

Authors:  Linda D Bobo; Erik R Dubberke; Marin Kollef
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

4.  Prevention and Treatment of Postsurgical Head and Neck Infections.

Authors:  Rebecca Fraioli; Jonas T. Johnson
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

5.  Clostridium difficile infection in hospitals: a brewing storm.

Authors:  Louis Valiquette; Donald E Low; Jacques Pépin; Allison McGeer
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

6.  Clostridium difficile colitis in children with cystic fibrosis.

Authors:  Sunny Zaheed Hussain; Cathy Chu; David P Greenberg; David Orenstein; Seema Khan
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

7.  Relapse versus reinfection: surveillance of Clostridium difficile infection.

Authors:  Mini Kamboj; Perminder Khosa; Anna Kaltsas; N Esther Babady; Crystal Son; Kent A Sepkowitz
Journal:  Clin Infect Dis       Date:  2011-10-05       Impact factor: 9.079

8.  Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection.

Authors:  Fnu Rafiullah; Sunil Kanwal; Usman M Majeed; Mark A Korsten; Faisal H Cheema; Munish Luthra; Muhammad Rizwan Sohail
Journal:  BMJ Case Rep       Date:  2011-11-21

9.  Comment on: Caution should be taken before operating on patients with Clostridium difficile colitis.

Authors:  R Bethune
Journal:  Ann R Coll Surg Engl       Date:  2010-05       Impact factor: 1.891

10.  Faecal microbiota transplantation for recurring Clostridium difficile infection in a patient with Crohn's disease and ileorectal anastomosis.

Authors:  Asser Mathiassen Oppfeldt; Jens F Dahlerup; Lisbet A Christensen; Christian L Hvas
Journal:  BMJ Case Rep       Date:  2016-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.